June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Toll-Like Receptor 4 Dependent Glaucomatous Retinal and Optic Nerve Head Damage
Author Affiliations & Notes
  • Emma Geiduschek
    Ophthalmology, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Timur Mavlyutov
    Ophthalmology, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Colleen M McDowell
    Ophthalmology, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Footnotes
    Commercial Relationships   Emma Geiduschek None; Timur Mavlyutov None; Colleen McDowell None
  • Footnotes
    Support  RO1EY026529
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1012. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emma Geiduschek, Timur Mavlyutov, Colleen M McDowell; Toll-Like Receptor 4 Dependent Glaucomatous Retinal and Optic Nerve Head Damage. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1012.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The cell-signaling mechanisms inducing damage and eventual retinal ganglion cell (RGC) death during glaucoma disease progression are still unknown. Recently, we identified DAMP (damage associated molecular pattern) activated toll-like receptor 4 (TLR4) signaling as a novel pathway involved in extracellular (ECM) regulation in the ONH. Here, we examined whether TLR4 and TGFβ2 signaling crosstalk is essential for increased extracellular matrix (ECM) deposition by primary ONH astrocytes. We also examined whether increased activation of TLR4 signaling by the DAMP, fibronectin extra domain A (FN-EDA), leads to a severe glaucoma phenotype in mice.

Methods : Human primary ONH astrocytes (N=3 strains) were isolated and exposed to exogenous TGFβ2 with or without the selective TLR4 inhibitor TAK-242 to quantify changes in ECM protein production by western blot and immunocytochemistry. We used our novel mouse model of glaucoma, B6.EDA+/+, which constitutively expressed the extra domain A (EDA) isoform of fibronectin. Intraocular pressure was measured using a rebound tonometer (N=10-12). RGC loss was measured via immunohistochemistry for RBPMS at one year (N=6-7) and two years (N=6-7) of age. Cells were counted in a masked manner 1400μm and 700μm from the ONH in all four quadrants of the retina.

Results : TGFβ2 induces fibronectin protein expression (p<0.05), but concurrent treatment with the selective TLR4 inhibitor TAK-242 blocks this effect (p>0.05) in human ONH primary astrocytes. IOP was significantly elevated in B6.EDA+/+ mice at both 1 and 2 years of age (p<0.001). At one year of age, total RGC counts are significantly decreased in B6.EDA+/+ mice (p<0.01) compared to age-matched controls. Interestingly, RGC loss was only significant in the peripheral sections of the retina (p<0.01) and not in the central sections (p>0.05). However, at two years of age, total RGC counts in B6.EDA+/+ mice are significantly decreased (p<0.05) and both central and peripheral areas each show significant decreases (p<0.05, p<0.05).

Conclusions : Here we show that TLR4 signaling is necessary for TGFβ2-dependent increases in ECM expression in ONH astrocytes. We also show constitutive activation of TLR4 by the DAMP FN-EDA generates a progressive glaucoma phenotype in our mouse model system. These results implicate TLR4 as an important regulator of glaucoma damage, providing a novel target pathway for new therapeutics.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×